Therapeutic plasma exchange followed by convalescent plasma transfusion in severe and critically ill COVID-19 patients: A single centre non-randomized controlled trial

Published: 11 July 2022| Version 1 | DOI: 10.17632/cvvgndh85f.1
Alex Novacescu


Data collected consisted of demographic patient data: age, sex, BMI and clinical data: comorbidities, onset of the viral infection to treatment (days), severity of the disease, apache II, length of stay, outcome, days of invasive mechanical ventilation, days of non-invasive ventilation, PaO2/Fio2, CRP, Ferritin, LDH before and 7 days after the treatment, antiviral of choice.


Steps to reproduce

Statistical data were analysed using GraphPad Prism 8 (GraphPad Software, Inc.) and IBM SPSS Statistics 20 (IBM Corp.). The category variables are characterized by value and percentage. Continuous variables are presented as mean (± standard deviation) and median (interquartile range). Data distribution testing was performed using the Shapiro-Wilk test. The numerical variables were compared with the t-test for independent samples or the Mann-Whitney U test, depending on the type of distribution of the variables. The χ2 test (or Fisher's exact test) was used for the nominal variables. The Kaplan-Meyer method with the log-rank (Mantel-Cox) test was applied to evaluate the primary endpoint. Cox regression was utilized to determine hazard ratio of the treatment group. All statistical tests were calculated with 2 tails and P<0.05 was considered to indicate a statistically significant difference.


Universitatea de Medicina si Farmacie Victor Babes din Timisoara


Therapeutics, Intensive Care, Therapeutic Plasma Exchange, COVID-19